Skip to main content

Table 3 Concomitant medication at baseline in CVOTs referred to in the text

From: Updates on cardiovascular outcome trials in diabetes

Concomitant medication @baseline Antihyperglycaemic medication N (%) CV treatment N (%)
Insulin Metformin Sulphonyl-urea Aspirin Statins Antiplatelet/anticoagulant Beta-blocker ACEI/ARB Other anti-hypertensives
SAVOR-TIMI53 6757 (40.9) 11,094 (67.4) 6332 (38.5) 12,390 (75.2) 12,892 (78.3) 13,386 (81.3) 10,117 (61.4) 12,935 (78.5) 6730 (40.9)
EXAMINE 1605 (29.8) 3562 (66.2) 2503 (69.9) 4881 (90.7) 4866 (90.4) 5232 (97.2) 4411 (81.9) 4411 (81.9) 1197 (22.2)
TECOS 3408 (23.2) 11,966 (81.6) 6645 (45.3) 11,518 (78.5) 11,719 (79.9) 3167 (21.7) 9322 (63.5) 11,555 (78.8) 4961 (33.8)
ELIXA 2292 (37.8) 3834 (63.2) 1863 (30.7) 5726 (94.4) 5621 (92.6) 480 (7.9) 5119 (84.4) 5151 (84.9) 1327 (21.9)
EMPA-REG OUTCOME 2374 (34.0)a 3933 (55.9)a 1383 (19.6) 5990 (85) 5387 (77) 4537 (64) 5651 (80) 2114 (30)
LEADER 4159 (45.0)a 7136 (76.4) 4721 (50) 5874 (63) 6729 (72) 6322 (67.7) 5173 (55.4) 7731 (83) 920 (9.85)
SUSTAIN 6 1 913 (58.0) 2414 (73.2) 1410 (42.8) 2108 (63.9) 2399 (72.8) 406 (12.3) 1894 (57.4) 2753 (83.5) 258 (7.8)
EXSCEL 6836 (46.3) 11,295 (76.6) 5401 (36.6) 9380 (63.6) 10,845 (73.5) 10,835 (73.5) 8211 (55.7) 11,788 (79.9)  
DEVOTE 6409 (83.9) 4564 (59.8) 2229 (29.2) 4764 (62.4) 5972 (78.2) 1599 (20.9) 4370 (57.2) 6182 (80.9) 2458 (32.2)
CANVAS program 5095 (50.2) 7825 (77.2) 4361 (43) 7599 (74.9) 7466 (73.6) 5421 (53.5)
ACE 6131 (94) 6066 (93) 6384 (98) 4301 (66) 3839 (59)
  1. aBoth mono and dual therapy